In a research note released yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of Prosensa Holding (RNA), and raised his price target to $17 (from …
In a research note released yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of Sarepta Therapeutics (SRPT), and a price target of $34.00.
In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of CTI Biophrarma Corp. (CTIC) …
In a research note released today, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of NeoGenomics Laboratories (NEO), and increased his price target to $7.00 (from …
In a research note released today, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of Sarepta Therapeutics, Inc. (SRPT), and a price target of $52.
In a research report released this morning, Roth Capital analyst Debjit Chattopadhyay initiated coverage on shares of PTC Therapeutics (PTCT). He issued a Buy …
In a report released this morning, Roth Capital analyst Debjit Chattopadhyay reiterated coverage on MacroGenics, Inc. (MGNX) with a Buy rating and a $30.
In a report released Tuesday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage on CTI BioPharma Corp (CTIC) with a Buy rating and a $4.00 price target, following yesterday’s news …
Roth Capital analyst Debjit Chattopadhyay today reiterated a “Buy” rating on shares of NeoGenomics Laboratories, Inc. (NEO), and a $6.
In a research note released this morning, Roth Capital analyst Debjit Chattopadhyay initiated coverage with a “Neutral” rating on Prosensa Holding N.V.
